Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity

Thrombosis Research

Volumn 100, Issue 5, 2000, Pages 433-441

  Josić, Djuro ^a   Hoffer, Lutz ^a   Buchacher, Andrea ^a   Schwinn, Horst ^a   Frenzel, Wolfgang ^a   Biesert, Lothar ^b   Klöcking, Hans Peter ^c   Hellstern, Peter ^d   Rokicka Milewska, Roma ^e   Klukowska, Anna ^e  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d KLINIKUM LUDWIGSHAFEN   (Germany)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Clotting factors II, VII, VIIa, IX and X; Protein C; Protein S; Protein Z; Prothrombin Complex Concentrate; Thrombogenicity; Vitamin K dependent proteins

Indexed keywords

ANTIVITAMIN K; FATTY ACID BINDING PROTEIN; PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN COMPLEX; VITAMIN K GROUP;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BLOOD CLOTTING; CHROMATOGRAPHY; DRUG MANUFACTURE; HUMAN; NANOFILTRATION; PRIORITY JOURNAL; SAFETY; SOLID PHASE EXTRACTION; THROMBOGENICITY; VIRUS INHIBITION;

ANIMALS; HUMANS; PROTHROMBIN; RATS; THROMBOSIS;

EID: 0034525056     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00339-X     Document Type: Article

References (30)

1. Integration of chromatography with traditional protein fractionation methods
2. Application of compact, porous tubes for preparative isolation of clotting factor VIII from human plasma
3. Separations in pharmaceutical manufacturing
4. Preparation of special plasma products
5. Emergency oral anticoagulant reversal. The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy
6. Management of acquired coagulation disorders in emergency and intensive-care medicine
7. Thrombogenicity of prothrombin complex concentrates
8. Clinical use of prothrombin complex concentrates. Report on thromboembolic complications
9. Considerations for recurrent and future management of haemophilia and its complications
10. Disseminated intravascular coagulation and myocardial infarction in a heamophilia B patient during therapy with prothrombin complex concentrates
11. Multi-organ failure after administration of PPSB in a patient with isolated factor VII deficiency
12. Activated factor VII. Presence in factor IX concentrates and persistence in the circulation
13. Factor VII and activated factor VII content of prothrombin complex concentrates
14. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates
15. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits
16. Summary report and recommendation of Task Force members and consultants
17. In vitro and in vivo correlation of clotting protease activity. Effect of heparin
18. Studies in intravascular coagulation. The pathogenesis of serum induced venous thrombosis
19. Preparation of the prothrombin complex
20. Chromatographic methods for fast purification of vitamin K-dependent clotting factors
21. Improved virus safety and purity of chromatographically produced Factor IX concentrate by nanofiltration
22. A double virus inactivated prothrombin complex concentrate with improved quality
23. Cold promoted activation of factor VII
24. Cleavage of Structural proteins during assembly of the head of bacteriophage T4
25. Thrombogenic potential of factor IX concentrates: Comparison of tests
26. In vitro spontaneous thrombin generation in human factor IX concentrates
27. Potentially thrombogenic materials in factor IX concentrates
28. Cold promoted activation of factor VII
29. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma
30. Value of virus filtration as a method for improving the safety of plasma products